产品编号 :
Cas No. :
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 95% | 询价 | |||
| 5mg | 95% | 询价 | |||
| 10mg | 95% | 询价 | |||
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 |
| 包装规格 | 纯度 | 目录价 | 会员专享价 | 库存 | 数量 |
|---|---|---|---|---|---|
| 1mg | 95% | 询价 | |||
| 5mg | 95% | 询价 | |||
| 10mg | 95% | 询价 | |||
| 25mg | 95% | 询价 | |||
| 50mg | 95% | 询价 |
CAS No. |
108524-93-2 |
|---|---|
中文名称 |
(3S,4R,4aR,6aR,6bS,8aS,11R,12R,12aS,14aR,14bR)-3,12-二羟基-4,6a,6b,11,12,14b-六甲基-8a-((((2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)羰基)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-二十氢并苯-4-羧酸 |
英文名称 |
(3S,4R,4aR,6aR,6bS,8aS,11R,12R,12aS,14aR,14bR)-3,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-((((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid |
别名 |
Ilexsaponin A1;Ilexgenin A 28-O-beta-D-glucopyranosyl ester;Ilexsaponin A;Ilexsaponin A1/ Ilexsaponina A;Urs-12-ene-23,28-dioicacid, 3,19-dihydroxy-, 28-b-D-glucopyranosyl ester, (3b,4b)-;Urs-12-ene-23,28-dioic acid, 3,19-dihydroxy-, 28-β-D-glucopyranosyl ester, (3β,4β)-;Ilexsaponin A1 >=95% (LC/MS-ELSD);Ilexsaponin A-RM |
标准英文名 |
(3S,4R,4aR,6aR,6bS,8aS,11R,12R,12aS,14aR,14bR)-3,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-8a-((((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid |
MDL No. |
MFCD24849334 |
分子式 |
C36H56O11 |
分子量 |
664.83 |
精确分子量 |
664.38 |
SMILES |
C[C@@H]1CC[C@]2(C(=O)O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@](C)(C(=O)O)[C@@H]5CC[C@]43C)[C@@H]2[C@]1(C)O |
标准SMILES |
C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@]1(C)O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O |
用途 |
Ilexsaponin A1 exhibits cardioprotective effects by alleviating myocardial ischemia-reperfusion injury through anti-apoptotic mechanisms; it reduces myocardial infarct size, decreases serum levels of LDH, AST, and CK-MB, enhances cell viability, and inhibits apoptosis in hypoxia/reoxygenation-induced cardiomyocytes; it downregulates pro-apoptotic proteins (caspase-3, cleaved caspase-3, and Bax), upregulates anti-apoptotic protein Bcl-2, and activates the Akt signaling pathway (increasing p-Akt expression) in both cellular and animal models of myocardial ischemia/reperfusion injury. |
InChIKey |
AWFZJSUJFSUBQU-MOJLLMCOSA-N |
UN No. |
2811 |
|---|
|
|
评论 |
|---|